Castrate resistant prostate cancer (CRPC) refers to prostate cancer that continues to grow and spread in the body despite medical or surgical therapy to reduce testosterone levels or block its actions. It is the most advanced stage of prostate cancer with limited treatment options. Biologics such as antibody drug conjugates and novel combination therapies have shown promise in managing symptoms and extending survival in men with CRPC.
The global Castrate Resistant Prostate Cancer Market is estimated to be valued at US$ 11.12 Bn in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increased adoption of emerging biologics and novel combination therapies is one of the key trends fueling the growth of the castrate resistant prostate cancer market. Antibody drug conjugates emerged as a promising therapeutic option and have shown survival benefits over the standard of care in clinical trials. For instance, enfortumab vedotin-ejfv demonstrated superior overall survival compared to chemotherapy in unselected patients with metastatic CRPC. Similarly, novel combination therapies such as apalutamide and abiraterone acetate administered together have shown improved radiographic progression-free survival and overall survival compared to either drug alone in men with metastatic CRPC. The biologics and novel combinations offer safe and effective targeted treatment options compared to chemotherapy and are expected to gain higher acceptance, thereby driving the market growth over the forecast period.
Segment Analysis
The global castrate resistant prostate cancer market is dominated by novel therapies segment. Novel therapies are a recent development in the treatment of castrate resistant prostate cancer. Drugs that fall under this segment such as novel hormonal agents, chemotherapy, immunotherapy and radiopharmaceuticals directly target tumor cells and have shown better efficacy compared to other traditional drug classes. This has resulted in novel therapies becoming the preferred option for treating castrate resistant prostate cancer.
Key Takeaways
The Global Castrate Resistant Prostate Cancer Market Demand is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis: North America is currently the dominant region for the castrate resistant prostate cancer market and is expected to maintain its dominance over the forecast period. Factors such as robust healthcare infrastructure, availability of advanced therapies and high healthcare spending have contributed to North America's large share.
Key players related content comprises: Key players operating in the castrate resistant prostate cancer market are Bucher Vaslin, Pera Pellenc, Scharfenberger, Zambelli Enotech, ENOTOOLS, Criveller Group, Della Toffola, Gruppo Bertolaso, Fabbri, Mori Luigi & C.
Explore more information on this topic, Please visit-
Research Nester released a report titled “Non-Metastatic Castration Resistant Prostate Cancer Treatment Market: Global Demand Analysis & Opportunity Outlook 2029”which delivers detailed overview of the global non-metastatic castration resistant prostate cancer treatment market in terms of market segmentation by therapy type, application and region.Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.The non-metastatic castration resistant prostate cancer (nmCRPC) treatment market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029 on account of the increasing elderly population and the rising prevalence of prostate cancer.
The National Cancer Institute of the U.S. Department of Health and Human Services, in the U.S., the estimated new cases and number of deaths from prostate cancer in the year 2020 were 191,930 and 33,330, respectively.Get Exclusive Sample Report Copy Of This Report @ https://www.researchnester.com/sample-request-2884The market is segmented by therapy type into chemotherapy, immunotherapy, radiotherapy, hormonal therapy, and others.
Among these segments, the hormonal therapy segment is anticipated to hold the largest share by the end of 2021 in the nmCRPC treatment market as a result of the higher positive diagnosis rates of hormonal therapy than other available treatments.
This can be attributed to the presence of leading healthcare providers in the region, especially in the United States, who are extensively involved in the research and development for innovative cancer treatment procedures.Increasing Ageing Population and Prostate Cancer Prevalence to Drive Market GrowthAccording to the United Nations, it is estimated that by 2050, every one in six people will be 65 years or older, i.e., 16% of the total world population.
It has been observed that individuals whose age is above 65 years or more possesses a high risk of having prostate cancer.
However, the expensive cost of cancer therapies and lack of awareness in low income economies are some factors that are estimated to restrain market growth in the near future.Get Exclusive Sample Report Copy Of This Report @ https://www.researchnester.com/sample-request-2884This report also provides the existing competitive scenario of some of the key players of the global non-metastatic castration resistant prostate cancer treatment market which includes company profiling of Pfizer Inc. (NYSE: PFE), Astellas Pharma Inc. (TYO: 4503), Johnson & Johnson Health Care Systems Inc. (NYSE: JNJ), Bayer AG (ETR: BAYN), Orion Corporation (HEL: ORNBV), Merck Sharp & Dohme Corp. (NYSE: MRK), Clovis Oncology (NASDAQ: CLVS), Novartis AG (SWX: NOVN), and AstraZeneca PLC (LON: AZN).
